TSHA
insider transactionsTaysha Gene Therapies, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-104.5K
0 buy · 104.5K sell
Net value · 365d
-$492.5K
$0 in · $492.5K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
3
0 buy · 104.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
10.2K sh
Own New
-
Grant·A
Director
$0
42.7K sh
Own New
-
Grant·A
Director
$0
21.3K sh
Own +2%
-
Grant·A
Director
$0
42.7K sh
Own New
-
Grant·A
Director
$0
21.3K sh
Own +20%
-
Grant·A
Director
$0
42.7K sh
Own New
-
Grant·A
Director
$0
21.3K sh
Own +20%
-
Grant·A
Director
$0
42.7K sh
Own New
-
Grant·A
Director
$0
21.3K sh
Own +10%
-
Grant·A
Director
$0
23.1K sh
Own New
-
Grant·A
Director
$0
1.9K sh
Own New
-
Sell·S
Kamran Alam KEY
CHIEF FINANCIAL OFFICER
$7.5K
1.7K sh · $4.52
Own -0%
-
Sell·S
Kamran Alam KEY
CHIEF FINANCIAL OFFICER
$109.9K
23.8K sh · $4.61
Own -2%
-
Sell·S
Kamran Alam KEY
CHIEF FINANCIAL OFFICER
$375.1K
79.0K sh · $4.75
Own -5%
-
Grant·A
Kamran Alam KEY
CHIEF FINANCIAL OFFICER
$0
231.0K sh
Own New
-
Grant·A
Kamran Alam KEY
CHIEF FINANCIAL OFFICER
$0
359.0K sh
Own +30%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Phillip B. Donenberg | Grant A | 12.5K | $0 |
| Jun 9, 2026 | Phillip B. Donenberg | Grant A | 10.2K | $0 |
| Jun 1, 2026 | John A Stalfort III | Grant A | 42.7K | $0 |
| Jun 1, 2026 | John A Stalfort III | Grant A | 21.3K | $0 |
| Jun 1, 2026 | Laura Sepp-Lorenzino | Grant A | 42.7K | $0 |
| Jun 1, 2026 | Laura Sepp-Lorenzino | Grant A | 21.3K | $0 |
| Jun 1, 2026 | Alison S Long | Grant A | 42.7K | $0 |
| Jun 1, 2026 | Alison S Long | Grant A | 21.3K | $0 |
| Jun 1, 2026 | Phillip B. Donenberg | Grant A | 42.7K | $0 |
| Jun 1, 2026 | Phillip B. Donenberg | Grant A | 21.3K | $0 |
| Apr 10, 2026 | Phillip B. Donenberg | Grant A | 23.1K | $0 |
| Feb 13, 2026 | Phillip B. Donenberg | Grant A | 1.9K | $0 |
| Feb 4, 2026 | Kamran Alam KEY | Sell S | 1.7K | $7.5K |
| Jan 26, 2026 | Kamran Alam KEY | Sell S | 23.8K | $109.9K |
| Jan 23, 2026 | Kamran Alam KEY | Sell S | 79.0K | $375.1K |
| Jan 12, 2026 | Kamran Alam KEY | Grant A | 231.0K | $0 |
| Jan 12, 2026 | Kamran Alam KEY | Grant A | 359.0K | $0 |
About TSHA insider trading
This page tracks insider transactions for Taysha Gene Therapies, Inc. (TSHA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.